Date: Tuesday, September 15, 2026
Time: 10:00 - 11:00 AM ET
Summary
Prepare your organization for the next era of global pricing and market access.
The US Most Favored Nation (MFN) pricing framework is rewriting how companies approach pricing architecture and launch sequencing across every market touched by its reference baskets. At the same time, the EU Joint Clinical Assessment (JCA) is raising the evidence bar across 27 member states, with orphan medicines next in line by 2028. Together, they are not just changing what companies do. They are changing what is possible.
Join us for a live panel discussion featuring global industry leaders, market access experts, and former policymakers as they examine how these policy shifts are affecting both established and emerging pharmaceutical companies. Drawing on insights from Certara’s original 2026 survey of market access professionals, the panel will explore the strategic implications of MFN and JCA, discuss where organizations are adapting their strategies, and examine what these changes mean for both mature and emerging markets.
Whether you’re preparing for future launches, developing global pricing strategies, or anticipating evolving evidence expectations, this webinar will provide timely perspectives to help inform your decision-making.
Register now
Senior Vice President, Certara – Session Moderator
Roman leads Certara’s evidence and access consulting practice, advising pharmaceutical companies on pricing strategy, value communication, and HTA engagement across global markets. He will moderate, present the survey data, and drive the discussion.
r-connect; Founder, European Access Academy (EAA)
Prof. Ruof leads the European Access Academy, a multi-stakeholder initiative on EU HTA harmonisation, and bridges industry and HTA perspectives. He will offer an analytical view on how JCA is reshaping European evidence expectations and what this means for market access strategy across diverse markets.
Founder of Watch Health Care Foundation
Krzysztof is a health policy expert with extensive leadership experience in Health Technology Assessment (HTA) and evidence-based health care across Central and Eastern Europe. He served as Poland’s Deputy Minister of Health (2015–2017), overseeing drug policy, reimbursement, and health investment decisions, and has held senior roles including CEO of HTA Audit, President of the Watch Health Care Foundation, and President of the Central & Eastern European Society of Technology Assessment in Health Care. He currently serves as President of the Ukrainian Society for Evidence-Based Health Care, CEO of MedInvest Scanner Ltd., and holds advisory roles with the European Parliament, MedTech Solutions Ltd., and NCBiR, alongside earlier international capacity-building work in Ukraine, Serbia, and with HTAi.
Group Market Access Manager | Ewopharma Group
Michał is an experienced market access and reimbursement professional at Ewopharma, with expertise in pharmaceutical policy, pricing, reimbursement, and market access strategies across Central and Eastern Europe. He has extensive experience working at the interface of the pharmaceutical industry and public healthcare, supporting access to innovative therapies and contributing to discussions on reimbursement policy and healthcare system development.
Executive Director, Global Pricing Strategy & Operations, Revolution Medicines
Jeff brings the perspective of a senior global pricing leader at a late-stage, multi-asset precision-oncology biotech, navigating global launch planning in a post-MFN environment. He will speak generally to how companies of that profile approach pricing architecture and launch sequencing for high-value oncology products across markets with very different economic capacities.
Register now
